We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WONDFO

Wondfo is a high-tech biological company focusing providing professional products and services for rapid diagnosis an... read more Featured Products: More products

Download Mobile App





Wondfo Exhibits Automatic Bench-Top CLIA Analyzers for POC Testing at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Wondfo (Guangzhou, China) will be exhibiting its automatic bench-top chemiluminescence immunoassay (CLIA) analyzers with advanced features for point of care (POC) testing at the 2022 AACC Clinical Lab Expo. More...



At AAC 2022, Wondfo is presenting its compact and automatic Accre 8 and Accre 90 CLIA bench-top analyzers which are 70% smaller than ordinary CLIA analyzers. With a single-dose reagent cartridge, the analyzers allow 600 days MTBF, requiring no extra consumables. The Accre 8 and Accre 90 enjoy both simple operation requiring only 30-minute training and reliable calibration & quality control system. Both the analyzers have a TAT time of 12-40 minutes and offer high sensitivity.

The Accre 8 has a throughput of up to 36 tests/hour and offers carry-over prevention. The Accre 90 has a throughput of up to 96 tests/hour and enables simultaneous processing of difference parameters with carry-over prevention. The Accre 8 and Accre 90 are designed for multiple application scenarios in emergency care, primary care and laboratories. Both the analyzers offer a broad menu of tests in the areas of thyroid, fertility, tumors, infectious diseases, cardiac, anemia, inflammation, bone metabolism and glycol metabolism.
 

Related Links:
Wondfo 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
All-in-One Molecular System
AIO M160
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.